Thus, the combination of eNOS-siRNA and UMMD may represent an improved anti-angiogenic therapy for NO-dependent disorders associated with increased microvascular permeability and angiogenesis, particularly cancer angiogenesis [44]. Here, NOS3 is linked to cancer.